Oss, Netherlands

Duncan Sperling


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Duncan Sperling: Innovator in Antitumor Drug Development

Introduction

Duncan Sperling is a notable inventor based in Oss, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of water-soluble analogs of paclitaxel, a well-known antitumor agent. His innovative work has the potential to enhance the efficacy and delivery of cancer treatments.

Latest Patents

Duncan Sperling holds a patent for "Water soluble analogs and prodrugs of paclitaxel." This invention relates to water-soluble antitumor analogs of paclitaxel, characterized by specific chemical formulas. The patent outlines the formulation of these analogs, which include various pharmaceutically acceptable counterions, and emphasizes their effectiveness as active ingredients in pharmaceutical compositions.

Career Highlights

Duncan is associated with Pharmachemie B.V., where he applies his expertise in pharmaceutical innovation. His work focuses on creating advanced drug formulations that can improve patient outcomes in cancer therapy. With a patent portfolio that includes 1 patent, he continues to contribute to the advancement of medical science.

Collaborations

Duncan collaborates with esteemed colleagues such as Peter H. G. Wiegerinck and Lesly Braamer. Their combined efforts in research and development foster an environment of innovation and excellence in the pharmaceutical industry.

Conclusion

Duncan Sperling's contributions to the field of pharmaceuticals, particularly through his patent on water-soluble analogs of paclitaxel, highlight his role as an innovator in cancer treatment. His work at Pharmachemie B.V. and collaborations with other professionals underscore the importance of teamwork in advancing medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…